CHLAMYDIA Sexually active women under Consider At least annually for For sexually active All pregnant women under 25 years of age 25 years of age screening young sexually active MSM individuals, screen men in high at sites of contact at first HIV Pregnant women, aged 25 years Sexually active women aged 25 prevalence (urethra, rectum) evaluation, and at and older if at increased risk years and older if at increased clinical settings regardless of condom least annually Retest during the 3rd trimester for risk or in populations use thereafter women under 25 years of age or at with high burden risk Retest approximately 3 months of infection (e.g. after treatment MSM) More frequent Pregnant women with chlamydial infection should have a Every 3 to 6 months if screening might be 3-4 weeks after treatment at increased risk appropriate and be retested within 3 months depending on individual risk behaviors and the local epidemiology Gonorrhea Sexually active women under All pregnant women under At annually for For sexually active individuals, screen at 25 years of age 25 years of age and older sexually active MSM first HIV evaluation, and women if at increased risk at sites of contact at least annually Sexually active women age 25 (urethra, rectum, thereafter years and older if at increased pharynx) More frequent screening risk regardless of condom be appropriate use depending on individual Retest 3 months after risk behaviors and the treatment local epidemiology Every 3 to 6 months if at increased risk SYPHILIS All pregnant women at the At least annually for For sexually active first prenatal visit sexually active MSM individuals, screen at first HIV
CHLAMYDIA Sexually active women under 25 years of age Sexually active women aged 25 years and older if at increased risk Retest approximately 3 months after treatment All pregnant women under 25 years of age Pregnant women, aged 25 years and older if at increased risk Retest during the 3rd trimester for women under 25 years of age or at risk Pregnant women with chlamydial infection should have a 3-4 weeks after treatment and be retested within 3 months Consider screening young men in high prevalence clinical settings or in populations with high burden of infection (e.g. MSM) At least annually for sexually active MSM at sites of contact (urethra, rectum) regardless of condom use Every 3 to 6 months if at increased risk For sexually active individuals, screen at first HIV evaluation, and at least annually thereafter More frequent screening might be appropriate depending on individual risk behaviors and the local epidemiology Gonorrhea Sexually active women under 25 years of age Sexually active women age 25 years and older if at increased risk Retest 3 months after treatment All pregnant women under 25 years of age and older women if at increased risk At annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use Every 3 to 6 months if at increased risk For sexually active individuals, screen at first HIV evaluation, and at least annually thereafter More frequent screening be appropriate depending on individual risk behaviors and the local epidemiology SYPHILIS All pregnant women at the first prenatal visit At least annually for sexually active MSM For sexually active individuals, screen at first HIV
CDC_%20STD%20Screening_Guidelines_15.docx